Screener
Immix Biopharma, Inc. IMMX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $4,730,152 | $5,442,737 |
| Accrued research and development expenses | 4,402,801 | 3,254,506 |
| Accrued professional services | 206,927 | - |
| Accrued compensation and related expenses | 880,671 | 942,163 |
| Other accrued expenses | 193,715 | 331,801 |
| Total accounts payable and accrued expenses | $10,414,266 | $9,971,207 |
Document
FAQ
- What is Immix Biopharma, Inc.'s accounts payable?
- Immix Biopharma, Inc. (IMMX) reported accounts payable of $4.73M in Q1 2026.
- How has Immix Biopharma, Inc.'s accounts payable changed year-over-year?
- Immix Biopharma, Inc.'s accounts payable decreased by 17.6% year-over-year, from $5.74M to $4.73M.
- What is the long-term trend for Immix Biopharma, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s accounts payable has grown at a 84.8% compound annual growth rate (CAGR), from $252.34K to $5.44M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Immix Biopharma, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude